CC Community News Digest (December 21-January 3)

Assorted news from the last two weeks:

NCI unveiled two new resources for young people with cancer:

Study suggests “that children in the U.S. may be treated more intensely compared to children in the U.K., which led to a decreased risk for death from recurrence or progression among childhood cancer survivors, but an increased risk for death due to a health condition likely caused by the cancer treatment among those in the U.S. cohort, such as a second cancer or cardiovascular disease.”

The University of Pittsburgh Graduate School of Public Health will receive a $2.5 million contract from the state of Pennsylvania to study the health effects of hydraulic fracturing, or fracking.  In recent years, dozens of cases of Ewing sarcoma, a rare bone cancer, and other childhood and young adult cancers have been identified in Washington, Greene, Fayette and Westmoreland counties, where shale gas sites are operating.

Pediatric cancer pain management requires balancing function with comfort.

Why is cancer on the rise in young people?

Rhabdomyosarcoma (RMS) is a highly malignant tumor and the most common soft tissue sarcoma in children. In spite of its clinical significance, less is known about genetic susceptibility to this malignancy compared to other pediatric cancers. Researchers at Baylor College of Medicine found that 7.3% of patients with RMS had clinically significant variant changes in cancer-predisposition genes compared to 1.4% of controls.

Upcoming Webinars and Online Opportunities:

Please register to attend the  9th ACCELERATE Paediatric Oncology Conference, 4-5 February 2021 (EU afternoons, US mornings).  The annual ACCELERATE Conference aims to strengthen international cooperation between academia, parent groups, biopharma companies, regulatory bodies and HTA bodies to improve and speed up the global development of new paediatric oncology drugs.  Please consider attending to:
  • LEARN from recent successes in paediatric oncology drug development worldwide;
  • HEAR about the latest regulatory updates in Europe and America;
  • DISCUSS in breakout sessions how to accelerate implementation new oncology drug development for children in this new global landscape;
  • SHARE advancements in the ACCELERATE program: Paediatric Strategy Forums and Working Groups (FAIR Trials, International Collaboration, Long Term Follow-Up Needs, Fit For Filing) and what is in the pipeline; and
  • STRENGTHEN multi-stakeholder international collaboration.

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.